Clene stock rallies 52% post-market on MS drug data

seekingalpha04-17

Shares of Clene (NASDAQ:CLNN) rallied 52% in post-market trading Tuesday after the company presented positive Phase 2 data for its drug CNM-Au8 in the treatment of multiple sclerosis, or MS. Clene ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428383754?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/495190234/image_495190234.jpg","is_english":true,"pubTime":"2024-04-17 05:20","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2428383754","market":"fut","top_or_hot":-1,"title":"Clene stock rallies 52% post-market on MS drug data","media":"seekingalpha","content":"<div>\n<p>Shares of Clene (NASDAQ:CLNN) rallied 52% in post-market trading Tuesday after the company presented positive Phase 2 data for its drug CNM-Au8 in the treatment of multiple sclerosis, or MS. Clene ...</p>\n\n<a href=\"https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clene stock rallies 52% post-market on MS drug data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClene stock rallies 52% post-market on MS drug data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 05:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Clene (NASDAQ:CLNN) rallied 52% in post-market trading Tuesday after the company presented positive Phase 2 data for its drug CNM-Au8 in the treatment of multiple sclerosis, or MS. Clene ...</p>\n\n<a href=\"https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLNN","symbol_name":"Clene Inc","start_time":0,"source_url":"https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data","article_id":"2428383754","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/495190234/image_495190234.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428383754","pubTimestamp":1713302423,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Clene  rallied 52% in post-market trading Tuesday after the company presented positive Phase 2 data for its drug CNM-Au8 in the treatment of multiple sclerosis, or MS. Clene said data from the long-term extension of its Phase 2 VISIONARY-MS study showed significant evidence of repair and remyelination across multiple paraclinical endpoints.  The company presented the data at the annual meeting of the American Academy of Neurology in Denver.More on Clene  Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLNN":"Clene Inc","BK4139":"生物科技"},"translate_title":"微软药品数据显示，克莱恩股市盘后上涨52%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLNN":1},"content_text":"Shares of Clene (NASDAQ:CLNN) rallied 52% in post-market trading Tuesday after the company presented positive Phase 2 data for its drug CNM-Au8 in the treatment of multiple sclerosis, or MS. Clene said data from the long-term extension of its Phase 2 VISIONARY-MS study showed significant evidence of repair and remyelination across multiple paraclinical endpoints.  The company presented the data at the annual meeting of the American Academy of Neurology in Denver. \n\nMore on Clene  Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428383754"}